BioSpace News Archive

OpGen, Inc. (Nasdaq: OPGN, “OpGen”), announced today the release of a new peer-reviewed publication that demonstrates the clinical utility of the Unyvero LRT panel and its potential impact on antibiotic use in hospitalized patients with suspected pneumonia compared to treatment directed based on microbiological culture results.

Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing products, today announced that Harry Stylli, Ph.D., CEO, chairman of the board, and co-founder of Progenity, is scheduled to participate in two upcoming virtual investor conferences: A presentation at Baird’s 2020 Global Healthcare Conference at 12:15 p.m. ET / 9:15 a.m. PT on September 9, 202

AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, today reported financial results for the second quarter ended June 30, 2020. “AlloVir has achieved important scientific and operational milestones that have us well positioned for growth,” said David Hallal, Chairman and Chief Executive Officer of AlloVir. “As we have advanced our portfolio of allogeneic, off -the-shelf, virus specific T cell therapies and are bolstered by

Syneos Health ® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization combining a CRO (Contract Research Organization) and a CCO (Contract Commercial Organization), today announced that Chief Executive Officer Alistair Macdonald and Chief Financial Officer Jason Meggs are scheduled to present at the Baird 2020 Global Healthcare conference on September 9, 2020, at 8:30 a.m. ET. A live webcast of the event, alon

BetterLife Pharma Inc., an emerging biotechnology company, announced that Dr. Eleanor Fish will continue to play a key role as part of the Company’s Scientific Advisory Board after having been appointed, in recognition of her expertise in infectious diseases, to the Canadian Government’s COVID-19 Task Force.

InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX: IN) (OTCQX: IMLFF), a clinical stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol (CBN), will report financial

Vibrent Health, a health technology company powering the future of precision medicine research, today announced that the National Institutes of Health (NIH) has awarded the company a new funding award to continue as the Participant Technology Systems Center (PTSC) of the All of Us Research Program.

Immunomedics, Inc., a leading biopharmaceutical company in the area of antibody-drug conjugates, announced that Dr. Behzad Aghazadeh, Executive Chairman, is scheduled to participate in virtual fireside chats at the following healthcare conferences

X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced the publication of comprehensive safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy data of mavorixafor from an ongoing Phase 2, open-label, dose-escalation and extension study in adult patients with genetically confirmed WHIM

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that it has appointed Mardi C. Dier as Executive Vice President and Chief Financial Officer (CFO), effective November 2, 2020.